Compare AbbVie Inc (ABBV) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Estee Lauder Companies Inc — how do they compare? AbbVie Inc trades at $253.81 (market cap $449.91B), while Estee Lauder Companies Inc trades at $81.64 (market cap $30.55B). The key difference: AbbVie Inc is far larger — about 14.7× Estee Lauder Companies Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | EL | |
|---|---|---|
Market Cap | $449.91B | $30.55B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $119.61 |
52-Week Low | $184.85 | $67.23 |
Enterprise Value | $513.38B | $36.72B |
Dividend Yield | 2.72% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Estée Lauder (EL) trades at $84.44, up 0.87% with a bullish technical signal and recent earnings beats. The stock shows strong momentum with three consecutive quarterly EPS beats and a consensus price target of $90.60. However, fundamentals reveal challenges with negative net income of -$1.13B in 2025 and elevated P/E of 147.8, though gross margins remain robust at 74.71%. Recent news highlights strategic investments and product innovation, including the Scent Scanner launch with Jo Malone London.
The outlook is mixed: technical strength and analyst optimism support upside to $90+, but high valuation and profitability concerns pose risks. Investment opportunity lies in execution of growth initiatives and margin recovery, while key risks include competitive pressures and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
